Article Text

other Versions

Download PDFPDF
Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS)
  1. Martin Mayer1,2
  1. 1Department of Physician Assistant Studies, College of Allied Health Sciences, East Carolina University, Greenville, North Carolina, USA
  2. 2Certified Physician Assistant, Vidant Medical Center, Greenville, North Carolina, USA
  1. Correspondence to : Professor Martin Mayer
    , Department of Physician Assistant Studies, College of Allied Health Sciences, 4310N Health Sciences Building, Mail Stop 668, East Carolina University, Greenville, NC 27858-4353, USA; mayerm{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The guidelines

The new joint guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC) for non-ST-elevation acute coronary syndromes (NSTE-ACS) represent the culmination of a massive undertaking to synthesise a large body of evidence, and the guideline writing committee is to be applauded for their efforts in preparing these guidelines.1 ,2 As is the current standard, the online version of these guidelines was published ahead of print, and review of the electronic publication ahead of print revealed that the handling of enoxaparin was problematic.1 The problem concerned the discussion of giving an initial 30 mg intravenous loading dose of enoxaparin prior to administering 1 mg/kg of enoxaparin subcutaneously every 12 h (q12h) when enoxaparin is selected as the anticoagulant. The electronic version published ahead of the print version simply stated “An initial intravenous loading dose is 30 mg.” (ref. 1, p.42). This or similar phrasing appeared on page 43 in the text and in table 7 as well. These statements are accompanied by a grade of A for level of evidence.

However, although the final guideline now says the initial 30 mg intravenous loading dose “has been used in selected patients” (ref. 2, pp.164–5), and thus does seem to make it clear that the loading dose is not mandatory, the guideline still does not adequately convey the details of the literature with respect to use of enoxaparin in NSTE-ACS.2 Guideline documents are plagued by space limitations in the setting of endeavours to summarise a large body of evidence, and this certainly may have contributed to the limited discussion of the data pertaining to the use of enoxaparin, but the details in this instance are important for clinicians to bear in mind when selecting enoxaparin as the anticoagulant when managing NSTE-ACS.

Pursuing the evidence

The only randomised controlled trial (RCT) that …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.